Darwin Global Management, Ltd.

Portfolio Overview

Darwin Global Management, Ltd. disclosed 6 positions worth $3.8B in its Form 13F-HR for Q1 2026, led by $INSM (INSMED Inc) at 68.3% of the equity portfolio, followed by $BLTE and $ABVX. During the quarter the fund opened 3 new positions and exited 3 — including a new stake in $RVMD. The portfolio is most concentrated in Healthcare (100.0% of disclosed assets). All figures are sourced directly from Darwin Global Management, Ltd.’s Form 13F-HR filing with the SEC under CIK 1839209.

• 

  INSMED Inc

  $INSM

  29.4#2,409

  Quality

  $2.6B16,805,184 sh
• 

  BELITE BIO, INC

  $BLTE

  —

  Quality

  $456.1M3,057,412 sh
• 

  Abivax S.A.

  $ABVX

  —

  Quality

  $352.1M3,468,657 sh
• 

  Revolution Medicines, Inc.

  $RVMD

  —

  Quality

  $205.0M2,211,018 sh
• 

  Roivant Sciences Ltd.

  $ROIV

  —

  Quality

  $179.5M6,797,300 sh
• 

  Dianthus Therapeutics, Inc. /DE/

  $DNTH

  26.8

  Quality

  $1.5M17,357 sh

Company	Quality	Value	Shares
INSMED Inc$INSM	29.4#2,409	$2.6B	16,805,184
BELITE BIO, INC$BLTE	—	$456.1M	3,057,412
Abivax S.A.$ABVX	—	$352.1M	3,468,657
Revolution Medicines, Inc.$RVMD	—	$205.0M	2,211,018
Roivant Sciences Ltd.$ROIV	—	$179.5M	6,797,300
Dianthus Therapeutics, Inc. /DE/$DNTH	26.8	$1.5M	17,357

Showing top 6 of 6 holdings.

Full Holdings — Darwin Global Management, Ltd. (Q1 2026)

All 6 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.

#	Ticker	Company	Value	Weight	QoQ	Quality
1	$INSM	INSMED Inc	$2.6B	68.3%	-20%	29.4
2	$BLTE	BELITE BIO, INC	$456.1M	12.1%	+1%	—
3	$ABVX	Abivax S.A.	$352.1M	9.3%	+9%	—
4	$RVMD	Revolution Medicines, Inc.	$205.0M	5.4%	NEW	—
5	$ROIV	Roivant Sciences Ltd.	$179.5M	4.8%	NEW	—
6	$DNTH	Dianthus Therapeutics, Inc. /DE/	$1.5M	0.0%	NEW	26.8